DSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer - PubMed
6 days ago
- #non-small cell lung cancer
- #immunotherapy
- #cancer stem cells
- DSG2+ cancer stem cells (CSCs) are co-located with FAP+ myofibroblasts (myCAFs) at the tumor boundary in non-small cell lung cancer (NSCLC).
- DSG2 is identified as a dominant marker for CSCs, associated with chemotherapy resistance and response to EGFR tyrosine kinase inhibitors.
- Spatial mapping shows DSG2+ CSCs enriched at tumor margins, co-localizing with FAP+ myCAFs that express MMP9 and MMP12.
- myCAFs enhance CSC-associated phenotypes in DSG2-high tumor cells in an MMP-dependent manner, contributing to therapeutic resistance.
- The study integrates single-cell RNA sequencing and spatial transcriptomics to define CSC-associated phenotypes in NSCLC.